Literature DB >> 23710501

Value of red targets and pattern deviation plots in visual field screening for hydroxychloroquine retinopathy.

Michael F Marmor1, Fred Y Chien, Mark W Johnson.   

Abstract

OBJECTIVE: To compare the value of red vs white 10-2 visual field testing in patients with different levels of hydroxychloroquine exposure and retinopathy in reference to recent American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy that advised the use of 10-2 visual field testing with a white test object.
METHODS: We studied retrospectively 13 patients using hydroxychloroquine who had undergone both red (FASTPAC) and white (SITA) 10-2 automated visual field testing in the course of their management. On clinical grounds, they were judged to have no retinopathy, early retinopathy, or moderate or severe hydroxychloroquine retinopathy.
RESULTS: White visual field diagrams were difficult to interpret, but pattern deviation plots consistently showed parafoveal sensitivity losses in early retinopathy. Red fields often showed more prominent scotomas in early retinopathy but sometimes showed irregular losses that were hard to evaluate. Either modality showed clear losses in moderate retinopathy. On repeated testing, the pattern deviation plots were somewhat more consistent than red fields in showing parafoveal damage.
CONCLUSIONS: With white 10-2 visual field hydroxychloroquine screening, the use of pattern deviation plots should be standard practice. Red testing appears to be more sensitive for early retinopathy but may be slightly less specific or consistent. We believe the main application for red testing is in screening for the earliest signs of retinopathy. Either red or white fields should be acceptable for hydroxychloroquine screening, as long as the clinician is sensitive to the characteristic patterns of early parafoveal damage and is prepared to retest fields and add objective tests.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23710501     DOI: 10.1001/jamaophthalmol.2013.1404

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  7 in total

1.  A comparison of structural and functional changes in patients screened for hydroxychloroquine retinopathy.

Authors:  Vivienne C Greenstein; Luz Amaro-Quireza; Evelyn S Abraham; Rithambara Ramachandran; Stephen H Tsang; Donald C Hood
Journal:  Doc Ophthalmol       Date:  2014-12-12       Impact factor: 2.379

2.  Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Hande Husniye Telek; Nilufer Yesilirmak; Gulten Sungur; Yaprak Ozdemir; Nesibe Karahan Yesil; Firdevs Ornek
Journal:  Doc Ophthalmol       Date:  2017-08-29       Impact factor: 2.379

3.  Evaluation of optical coherence tomography angiography parameters in patients treated with Hydroxychloroquine.

Authors:  Mohammadreza Akhlaghi; Farzan Kianersi; Hamed Radmehr; Alireza Dehghani; Afsaneh Naderi Beni; Pegah Noorshargh
Journal:  BMC Ophthalmol       Date:  2021-05-11       Impact factor: 2.209

4.  Scotoma analysis of 10-2 visual field testing with a red target in screening for hydroxychloroquine retinopathy.

Authors:  David J Browning; Chong Lee
Journal:  Clin Ophthalmol       Date:  2015-08-20

5.  Scotoma analysis of 10-2 visual field testing with a white target in screening for hydroxychloroquine retinopathy.

Authors:  David J Browning; Chong Lee
Journal:  Clin Ophthalmol       Date:  2015-05-27

Review 6.  Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review.

Authors:  A Geamănu Pancă; A Popa-Cherecheanu; B Marinescu; C D Geamănu; L M Voinea
Journal:  J Med Life       Date:  2014-09-25

7.  Visual field examinations using different strategies in Asian patients taking hydroxychloroquine.

Authors:  Ko Eun Kim; So Jung Ryu; Young Hwan Kim; Yuchan Seo; Seong Joon Ahn
Journal:  Sci Rep       Date:  2022-08-30       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.